

volume of the resultant preparation, remove an accurately measured representative portion from each container. Dilute the solution thus obtained with sufficient distilled water to obtain a solution containing 1 milligram of cefmenoxime per milliliter (estimated). Transfer 4.0 milliliters of this solution to a 50-milliliter volumetric flask, add 20 milliliters of internal standard solution and dilute to volume with mobile phase to obtain a solution containing 80 micrograms of cefmenoxime per milliliter (estimated).

(iii) *System suitability requirements—*

(A) *Tailing factor.* The tailing factor (*T*) for the cefmenoxime peak is satisfactory if it is not more than 1.6 at 5 percent of peak height.

(B) *Efficiency of the column.* The efficiency of the column (*n*) is satisfactory if it is greater than 1,200 theoretical plates for the cefmenoxime peak.

(C) *Resolution.* The resolution (*R*) between the peak for cefmenoxime and phthalimide is satisfactory if it is not less than 2.3.

(D) *Coefficient of variation.* The coefficient of variation (*S_R* in percent) of 5 replicate injections is satisfactory if it is not more than 2.0 percent. If the system suitability requirements have been met, then proceed as described in § 436.363(b) of this chapter.

(iv) *Calculations—*(A) *Micrograms per milligram.* Calculate the micrograms of cefmenoxime per milligram as follows:

$$\frac{\text{Micrograms of cefmenoxime per milligram}}{= \frac{T3R_u \times P_3 \times 100 \times d}{R_s \times C_u (100 - L - S)}}$$

where:

R_u=Area of the cefmenoxime peak in the chromatogram of the sample/Area of internal standard peak;

R_s=Area of the cefmenoxime peak in the chromatogram of the cefmenoxime working standard/Area of internal standard peak;

P₃=Cefmenoxime activity in the cefmenoxime working standard solution in micrograms per milliliter;

C_u=Milligrams of sample per milliliter of sample solution;

d=Dilution factor of the sample;

L=Percent loss on drying (determined as directed in paragraph (b)(4) of this section); and

S=Percent sodium carbonate (determined as directed in paragraph (b)(6) of this section).

(B) *Milligrams of cefmenoxime per vial.* Calculate the cefmenoxime content of the vial as follows:

$$\frac{\text{Milligrams of cefmenoxime per vial}}{= \frac{R_u \times P_s \times d}{R_s \times 1,000}}$$

where:

R_u=Area of the cefmenoxime peak in the chromatogram of the sample/Area of internal standard peak;

R_s=Area of the cefmenoxime peak in the chromatogram of the cefmenoxime working standard/Area of internal standard peak;

P_s=Cefmenoxime activity in the cefmenoxime working standard solution in micrograms per milliliter; and

d=Dilution factor of the sample.

(2) *Sterility.* Proceed as directed in § 436.20 of this chapter, using the method described in paragraph (e)(1) of that section.

(3) *Pyrogens.* Proceed as directed in § 436.32(b) of this chapter, using a solution containing 60 milligrams of cefmenoxime per milliliter.

(4) *Loss on drying.* Proceed as directed in § 436.200(a) of this chapter.

(5) *pH.* Proceed as directed in § 436.202 of this chapter, using an aqueous solution containing 100 milligrams per milliliter.

(6) *Sodium carbonate content.* Proceed as directed in § 436.364 of this chapter.

[53 FR 13403, Apr. 25, 1988; 53 FR 19369, May 27, 1988]

§ 442.223 Sterile cephaloridine.

The requirements for certification and the tests and methods of assay for sterile cephaloridine packaged for dispensing are described in § 442.23a.

[39 FR 19040, May 30, 1974, as amended at 55 FR 11583, Mar. 29, 1990]

§ 442.225 Cephalothin sodium injectable dosage forms.

§ 442.225a Sterile sodium cephalothin.

The requirements for certification and the tests and methods of assay for sterile sodium cephalothin packaged for dispensing are described in § 442.25a.

[39 FR 19040, May 30, 1974. Redesignated at 40 FR 11351, Mar. 11, 1975]